Program
repaglinide
Also written as “Repaglinide”, “repaglinide and metformin combination tablet” and “Repaglinide/Metformin combination, Repaglinide, Metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Overweight · Gastrointestinal Stromal Tumors · Gout, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 130 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Eli Lilly | 30 open or running | phase 1since Jul 20, 2022 | Jul 20, 2022 | none ahead |
| dalim-biotech-co-ltd | 10 open or running | phase 1since Jan 29, 2013 | Jan 29, 2013 | none ahead |
| Merck | 10 open or running | phase 4since Oct 16, 2012 | Oct 16, 2012 | none ahead |
Also a collaborator on its studies: basilea-pharmaceutica-international-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 25, 2007First study: phase 4 study in Diabetes MellitusNew to Novo NordiskNovo Nordisk · NCT00491725 · 187 enrolled · China
- Dec 4, 20072 phase 4 studies in Diabetes MellitusNovo Nordisk · NCT00568984, NCT00568074
- Nov 26, 2008Phase 4 study in Diabetes MellitusNovo Nordisk · NCT00799448 · 40 enrolled · Greece
- Aug 13, 2009Phase 1 study in Diabetes MellitusNovo Nordisk · NCT00959101 · 42 enrolled · China
- Nov 26, 2009Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01022762 · 440 enrolled · China
- Dec 8, 20112 phase 1 studies in Diabetes MellitusNovo Nordisk · NCT01490658, NCT01489644
- Mar 22, 2012Phase 3 study in Diabetes MellitusNovo Nordisk · NCT01562561 · 213 enrolled · Hong Kong, Malaysia, Philippines and more
- May 16, 2012Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01605773 · 51 enrolled · United States
- Oct 1, 20123 phase 4 studies in Diabetes MellitusNovo Nordisk · NCT01698931, NCT01720303, NCT01720290
- Oct 16, 2012Merck's first study: phase 4 study in Diabetes Mellitus, Type 2New to MerckMerck · NCT01709305 · 5,570 enrolled
- Jan 29, 2013dalim-biotech-co-ltd's first study: phase 1 study in Diabetes Mellitus, Type 2New to dalim-biotech-co-ltddalim-biotech-co-ltd · NCT01780051 · 48 enrolled · Korea, Republic of
- Jul 20, 2022Eli Lilly's first study: phase 1 study in HealthyNew to Eli LillyEli Lilly · NCT05469113 · 16 enrolled · United States
- Nov 30, 2023Phase 1 study in HealthyEli Lilly · NCT06165146 · 16 enrolled · United States
- Jul 10, 2024Phase 1 study in HealthyEli Lilly · NCT06503679 · 49 enrolled · United States
TargetBeta
“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mitigliniderule | Kissei Pharmaceutical | phase 4 | 9 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06503679Healthy · United States | 1 | Completed | Eli Lilly | Dec 31, 2024 | 49 |
| NCT06165146Healthy · United States | 1 | Completed | Eli Lilly | Dec 30, 2020 | 16 |
| NCT05469113Healthy · United States | 1 | Completed | Eli Lilly | Mar 5, 2019 | 16 |
| NCT01780051Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | dalim-biotech-co-ltd | Apr 2013 | 48 |
| NCT01720303Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Apr 10, 2003 | 159 |
| NCT01720290Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Feb 25, 2003 | 150 |
| NCT01709305Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Apr 17, 2015 | 5,570 |
| NCT01698931Diabetes Mellitus · Italy | 4 | Completed | Novo Nordisk | Mar 6, 2003 | 9 |
| NCT01605773Diabetes Mellitus · United States | 4 | Completed | Novo Nordisk | Mar 13, 2003 | 51 |
| NCT01562561Diabetes Mellitus · Hong Kong, Malaysia, Philippines and more | 3 | Completed | Novo Nordisk | Dec 20, 2002 | 213 |
| NCT01490658Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Aug 2006 | 93 |
| NCT01489644Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Jul 2006 | 62 |
| NCT01022762Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Nov 2010 | 440 |
| NCT00959101Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Oct 2009 | 42 |
| NCT00799448Diabetes Mellitus · Greece | 4 | Terminated | Novo Nordisk | Sep 20, 2004 | 40 |
| NCT00568984Diabetes Mellitus · China, Malaysia, Philippines and more | 4 | Completed | Novo Nordisk | Nov 10, 2003 | 324 |
| NCT00568074Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Sep 2, 2004 | 131 |
| NCT00491725Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Jun 2006 | 187 |
How it is read
Names in the registry
- “Repaglinide”, 15 entries
- “repaglinide”, 13 entries
- “repaglinide and metformin combination tablet”, 2 entries
- “Repaglinide/Metformin combination, Repaglinide, Metformin”, 2 entries
- “repaglinide 0.5 mg tablet”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Obesity, 1 study
- Overweight, 1 study
- Gastrointestinal Stromal Tumors, 1 study
- Gout, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.